Want to see FR:AKE full AI Analyst Report?
Top Page
Arkema
(AKE)
Select Model
Select Model
Rating:60Neutral
Price Target:
€64.00
▲(14.70% Upside)
Action:Reiterated
Date:08/04/26
The score is held back primarily by weak financial performance—near break-even net margins, deteriorated returns, and higher leverage—despite a strong revenue rebound. Technicals are a notable positive with the stock trading above major moving averages and positive momentum indicators. Valuation remains a key risk given the very high P/E, partially offset by a strong dividend yield.
Positive Factors
Revenue Recovery
A 37% TTM revenue rebound indicates restored end-market demand and higher utilization across plants. Sustained top-line recovery can underwrite needed margin improvement, support investment in specialty lines, and provide a multi-month runway for operational deleveraging.
Negative Factors
Weak Profitability
Margins have compressed materially despite strong revenue, leaving minimal earnings cushion. Near-zero net margin constrains the firm's ability to absorb cost shocks, invest in R&D or sustain returns, and makes earnings highly sensitive to input-cost swings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
A 37% TTM revenue rebound indicates restored end-market demand and higher utilization across plants. Sustained top-line recovery can underwrite needed margin improvement, support investment in specialty lines, and provide a multi-month runway for operational deleveraging.
Read all positive factors
Arkema (AKE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€4.46B
Dividend Yield6.11%
Average Volume (3M)234.51K
Price to Earnings (P/E)103.3
Beta (1Y)1.47
Revenue Growth-5.73%
EPS Growth-73.67%
CountryFR
Employees20,648
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.57
Shares Outstanding76,060,830
10 Day Avg. Volume237,321
30 Day Avg. Volume234,507
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)0.65
Price to Sales (P/S)0.43
P/FCF Ratio11.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.14Price Target Upside0.61% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)4.7
Revenue Forecast (FY)€9.15B
Arkema Business Overview & Revenue Model
Company Description
Arkema S.A. operates as a global producer and distributor of specialty chemicals and advanced materials. Its operations are strategically divided into four key business segments: Adhesive Solutions, Advanced Materials, Coating Solutions, and Inter...
How the Company Makes Money
Arkema makes money primarily by manufacturing and selling specialty chemicals and materials to industrial customers under multi-year customer relationships and recurring demand tied to downstream manufacturing activity. Its revenue is mainly gener...
Arkema Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.90B | 9.07B | 9.54B | 9.51B | 11.55B | 9.52B |
| Gross Profit | 1.59B | 1.61B | 1.94B | 1.96B | 2.58B | 2.14B |
| EBITDA | 1.16B | 1.25B | 1.31B | 1.33B | 1.82B | 2.27B |
| Net Income | 60.00M | 63.00M | 354.00M | 402.00M | 965.00M | 1.31B |
Balance Sheet | ||||||
| Total Assets | 14.17B | 14.24B | 15.21B | 14.52B | 13.51B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 2.20B | 2.01B | 2.04B | 1.59B | 2.29B |
| Total Debt | 4.27B | 5.36B | 4.55B | 4.28B | 3.26B | 2.76B |
| Total Liabilities | 7.21B | 8.01B | 7.45B | 7.06B | 6.17B | 5.95B |
| Stockholders Equity | 6.78B | 6.04B | 7.53B | 7.20B | 7.30B | 6.30B |
Cash Flow | ||||||
| Free Cash Flow | 372.50M | 337.00M | 353.00M | 622.00M | 766.00M | 152.00M |
| Operating Cash Flow | 915.60M | 973.00M | 1.12B | 1.26B | 1.50B | 915.00M |
| Investing Cash Flow | -535.60M | -616.00M | -940.00M | -1.35B | -2.34B | 473.00M |
| Financing Cash Flow | -220.60M | -262.00M | -207.00M | 516.00M | 168.00M | -652.00M |
Arkema Technical Analysis
Positive
55.80
Price Trends
57.53
Positive
57.24
Positive
53.95
Positive
Market Momentum
1.31
Negative
63.76
Neutral
83.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AKE, the sentiment is Positive. The current price of 55.8 is below the 20-day moving average (MA) of 57.67, below the 50-day MA of 57.53, and above the 200-day MA of 53.95, indicating a bullish trend. The MACD of 1.31 indicates Negative momentum. The RSI at 63.76 is Neutral, neither overbought nor oversold. The STOCH value of 83.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AKE.
Arkema Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €108.74B | 29.23 | 13.87% | 1.73% | -1.30% | 3.05% | |
60 Neutral | €4.46B | 103.33 | 0.62% | 6.45% | -5.73% | -73.67% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €124.23M | -3.62 | -18.56% | ― | ― | ― | |
49 Neutral | €105.10M | -5.10 | -26.54% | ― | -20.58% | -41.43% |
* General Sector Average
FR:AKE
Arkema
61.45
4.17
7.28%
FR:AI
Air Liquide
172.38
18.85
12.28%
FR:ALCRB
Carbios SA
6.91
-2.28
-24.77%
FR:ALAFY
AFYREN
2.89
0.25
9.70%
FR:ALDUB
Encres Dubuit SA
2.00
-0.40
-16.67%
FR:MLPRX
Parx Materials NV
0.40
0.16
66.67%
Arkema Corporate Events
Arkema Lifts Margin and Confirms 2026 Guidance Amid Cost Surge and Geopolitical Strain
Jul 30, 2026
Arkema reported a resilient second quarter despite the conflict in the Middle East and weak global demand, posting EBITDA of €391 million, up 7.4% year-on-year, and lifting its EBITDA margin to 16.1%. Sales rose 1.3% to €2.43 billion, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.